Theresa Madigan1, Christine B Teng2, Jena Koshaish3, Kent R Johnson4, Kevin K Graner4, Ritu Banerjee2. 1. Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota. 2. Division of Pediatric Infectious Diseases, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota. 3. Department of Pharmacy, All Children's Hospital, St. Petersburg, Florida. 4. Pharmacy Services, Mayo Clinic, Rochester, Minnesota.
Abstract
OBJECTIVE: To compare vancomycin serum trough concentrations and 24-hour area under the serum concentration-versus-time curve (AUC24) among very low-birth-weight (VLBW) premature infants before and after implementation of an institution-wide increase in neonatal vancomycin dosing. STUDY DESIGN: We performed a retrospective analysis of vancomycin concentrations among preterm VLBW neonates before (2007-2010) and after (2010-2013) implementation of a new vancomycin dosing protocol consisting of increased vancomycin daily dose and frequency of administration. RESULTS: Neonates weighing < 1,500 g and receiving the new vancomycin dosing regimen had lower rates of undetectable trough concentrations (24 vs. 50%, p = 0.04), higher median trough concentrations (10.8 vs. 5.9 µg/mL, p = 0.003), a higher proportion of goal trough concentrations of 10 to 20 µg/mL (35 vs. 4%, p = 0.005), and a significantly higher vancomycin AUC24 (438 vs. 320 mg·h/L, p = 0.004) compared with historical controls. CONCLUSION: Increasing the vancomycin daily dose and dosing frequency led to an increase in vancomycin trough concentrations and AUC24, and a decrease in the proportion of undetectable (< 5.0 µg/mL) troughs, without an increase in toxicity among VLBW premature neonates. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
OBJECTIVE: To compare vancomycin serum trough concentrations and 24-hour area under the serum concentration-versus-time curve (AUC24) among very low-birth-weight (VLBW) premature infants before and after implementation of an institution-wide increase in neonatal vancomycin dosing. STUDY DESIGN: We performed a retrospective analysis of vancomycin concentrations among preterm VLBW neonates before (2007-2010) and after (2010-2013) implementation of a new vancomycin dosing protocol consisting of increased vancomycin daily dose and frequency of administration. RESULTS: Neonates weighing < 1,500 g and receiving the new vancomycin dosing regimen had lower rates of undetectable trough concentrations (24 vs. 50%, p = 0.04), higher median trough concentrations (10.8 vs. 5.9 µg/mL, p = 0.003), a higher proportion of goal trough concentrations of 10 to 20 µg/mL (35 vs. 4%, p = 0.005), and a significantly higher vancomycin AUC24 (438 vs. 320 mg·h/L, p = 0.004) compared with historical controls. CONCLUSION: Increasing the vancomycin daily dose and dosing frequency led to an increase in vancomycin trough concentrations and AUC24, and a decrease in the proportion of undetectable (< 5.0 µg/mL) troughs, without an increase in toxicity among VLBW premature neonates. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
Authors: E V Capparelli; J R Lane; G L Romanowski; E J McFeely; W Murray; P Sousa; C Kildoo; J D Connor Journal: J Clin Pharmacol Date: 2001-09 Impact factor: 3.126
Authors: Brian J Anderson; Karel Allegaert; John N Van den Anker; Veerle Cossey; Nicholas H G Holford Journal: Br J Clin Pharmacol Date: 2006-07-21 Impact factor: 4.335
Authors: O Plan; G Cambonie; E Barbotte; P Meyer; C Devine; C Milesi; O Pidoux; M Badr; J C Picaud Journal: Arch Dis Child Fetal Neonatal Ed Date: 2008-05-01 Impact factor: 5.747
Authors: R Silva; E Reis; M A Bispo; A M Almeida; I M Costa; F Falcão; J M Palminha; A C Falcão Journal: J Pharm Pharmacol Date: 1998-11 Impact factor: 3.765
Authors: Michael J Rybak; Ben M Lomaestro; John C Rotschafer; Robert C Moellering; William A Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine Journal: Pharmacotherapy Date: 2009-11 Impact factor: 4.705
Authors: Matthijs de Hoog; Bert A van Zanten; Wim C Hop; Ellen Overbosch; Nynke Weisglas-Kuperus; John N van den Anker Journal: J Pediatr Date: 2003-01 Impact factor: 4.406